D. Ross Camidge
MD, PhD
Joyce Zeff Chair in Lung Cancer Research; Director, Thoracic Oncology
👥Biography 个人简介
D. Ross Camidge is internationally recognized for his landmark work on ALK resistance mechanisms and development of next-generation ALK inhibitors. He led early trials of lorlatinib establishing its efficacy against compound ALK mutations arising after sequential therapy. His research has systematically catalogued the resistance landscape of ALK inhibitors and proposed rational sequential treatment strategies. He is a sought-after speaker and has shaped global guidelines for ALK-positive NSCLC management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 D. Ross Camidge 的研究动态
Follow D. Ross Camidge's research updates
留下邮箱，当我们发布与 D. Ross Camidge（University of Colorado Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment